NorthWest Biotherapeutics Inc (NWBO)

[Arby2000]

Perhaps Dr. Liau will focus on how they have overcome the challenges with imunotharapy and discuss the OS results and the long tail they have achieved. If she does not discuss results in the format that is traditionally expected of a TLD announcement - meeting primary and secondary end points and numbers typically included in such an announcement - then would that be a way to give the science and medical community (and the market) an insight into the effectiveness of the therapy without a 'formal' TLD announcement?

Very likely someone will ask the question about meeting endpoints and she may have a prepared response that defers TLD announcement to NWBO.